New eczema drug tested on 1000 people for itch relief and skin clearing

NCT ID NCT07276620

Summary

This study is testing an already-approved eczema medication called ivarmacitinib in a real-world setting. It will enroll 1000 adolescents and adults with moderate-to-severe atopic dermatitis to see how well it controls itching, clears skin rashes, and prevents flare-ups. The main goal is to gather more safety data and understand which patients benefit most from different treatment plans.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.